



**REMARKS**

Entry of the above amendment prior to examination is respectfully requested.

Please substitute the clean copy of the description of Figure 2. Applicants inadvertently referred to Figures 2A and 2B in the originally filed specification. However, they provided only Figure 2. Figure 2 is the correct figure as originally submitted.

The specification has been amended in accordance with C.F.R. 1.821 through 825 to add the Sequence Listing. Applicants enclose with the amendment a CRF copy of the Sequence Listing and a declaration under 37 CFR 1.821.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Version With Markings To Show Changes Made.**"

If in the opinion of the Examiner a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 846-7555.

Respectfully submitted,

Christopher L. Stone  
Registration No. 35,696

Date:

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Phone: (650) 846-7555  
Facsimile: (650) 845-6504



**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the specification:**

Paragraph beginning at line 27 of page 4 has been amended as follows:

[Figures 2A and 2B are] Figure 2 is a photograph[s] of a gel of PCR amplified DNA fragments after lysis of target bound phage, [Figure 2A illustrates] including TNF- $\alpha$  bound phage and [Figure 2B illustrates] IL-6 and IL-8 bound phage.